WO2008010472A1 - Total enteral nutrition composition - Google Patents
Total enteral nutrition composition Download PDFInfo
- Publication number
- WO2008010472A1 WO2008010472A1 PCT/JP2007/064056 JP2007064056W WO2008010472A1 WO 2008010472 A1 WO2008010472 A1 WO 2008010472A1 JP 2007064056 W JP2007064056 W JP 2007064056W WO 2008010472 A1 WO2008010472 A1 WO 2008010472A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- enteral nutrition
- content
- composition according
- nutrition composition
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Definitions
- the present invention requires a novel nutritional composition, more specifically, nutritional support for the elderly, hospitalized patients, and the like, and a nitrogen source in the form of a protein that is free from organic changes and disorders in the digestive tract is a nutrient.
- the present invention relates to a general enteral nutrition composition for humans that can be used. In other words, proteins, fats, vitamins, minerals, etc. are effective when digestive absorption is attenuated due to aging or undernutrition, etc., without inflammation, necrosis, excision, motor paralysis, ileus, etc.
- the present invention relates to a comprehensive enteral nutrition composition that can be absorbed and replenished efficiently and restore nutritional status.
- Enteral nutritional compositions that comprehensively include proteins, lipids, carbohydrates, vitamins, and minerals for subjects who need nutritional supplementation are known (Patent Document 1). This is only this A nutritional composition that enables nutritional management at the same time, including a specific proportion of milk protein and soy protein in the protein raw material in the composition, and omega-3 fatty acid and omega-6 fatty acid in the lipid It is characterized by inclusion at a specific ratio. Also known is a general enteral nutritional product that is made up of proteins, lipids, carbohydrates, emulsifiers, and hydraulics, and that specifies osmotic pressure and amino acid score (Patent Document 2).
- enteral nutritional compositions that contain a high balance of nutritional components and high concentrations of vitamins, minerals, and other nutrients are important. For this reason, entero nutritional composition lOOmL that can be ingested by lOOkcal is sold on the market, and the demand is expected to increase in the future.
- enteral nutrition is effective in improving serum albumin levels, which are nutritional indicators, maintaining appropriate concentrations of copper, zinc, sodium, etc. in blood and improving pressure ulcers.
- the drug is not yet known.
- the necessary ingredients are appropriately selected from the comprehensive viewpoint of combining a large amount of purified proteins and lipids with high purity and appropriately containing vitamins for smooth energy production in vivo.
- the combined total enteral nutritional composition has not been supplied so far.
- increasing the sodium content of nutritional compositions rich in protein has been limited in the past because of protein precipitation (salt prayer).
- salt prayer protein precipitation
- it since it may cause hyponatremia in the elderly, it is extremely important to increase the sodium content at the same time as the protein content in the Takagi Nerghi Total Enteral Nutrient Composition.
- Glutamic acid has long been used as a seasoning in foods as an umami component. Recent research has revealed that glutamic acid promotes the excretion of food gastric power and has a positive effect on the gastrointestinal tract (Non-patent Document 1). It has been reported that glutamic acid and 5′-nucleotide are effective in reducing diarrhea when there is an organic disorder in the digestive tract, such as after a large operation (Patent Document 3). Glutamate and 5'-nucleotide are also useful for functional gastroenteropathy such as abdominal pain, stomach sag, heartburn, etc. It is disclosed that it is effective for functional gastroenteropathy and gastroesophageal reflux disease in the upper gastrointestinal tract of esophageal reflux (Patent Document 4).
- Patent Document 1 Japanese Patent No. 3102645
- Patent Document 2 JP 2004-51494 A
- Patent Document 3 WO2006 / 001492
- Patent Document 4 WO2006 / 030980
- Non-Patent Literature 1 Gastroenterology: 130 ⁇ , No. 4, Supple 2, A246, 2006
- An object of the present invention is to provide an improved comprehensive system capable of supplying all the nutrients necessary for a person who cannot receive sufficient nutrition through meals, such as the elderly and hospitalized patients.
- Providing an enteral nutritional composition Specifically, proteins, fats, and carbohydrates that are effective in improving serum albumin levels and pressure ulcers, which are nutritional indicators, and in improving blood mineral balance and remarkably improving the recovery of undernutrition.
- the aim is to provide a comprehensive enteral nutritional composition containing vitamins and minerals, especially zinc and copper, and also containing glutamic acid and 5'-nucleotide to improve the state of the intestinal tract and enhance absorption capacity.
- the total enteral nutrition composition of the present invention is used for humans who do not have an organic disorder of the gastrointestinal tract, and includes proteins, carbohydrates, fats, minerals, and vitamins, and has the following characteristics. By combining them together, the intended purpose is achieved.
- Composition lOOkcal contains 165 mg or more of sodium, and contains at least one selected from glutamic acid, dipeptides or tripeptides containing glutamic acid, 5 ′ nucleotides or their salt strength.
- glutamic acid dipeptides or tripeptides containing glutamic acid, 5 ′ nucleotides or their salt strength.
- it is necessary to contain a high concentration of sodium High concentrations of sodium cause protein precipitation due to salt prayer when the protein concentration is high, but this problem can be prevented by using sodium phosphate, sodium citrate, etc. as the main sodium source.
- glutamic acid, dipeptide or tripeptide containing glutamic acid, 5 'nucleotide or their salts can be added to enhance the state of epithelial tissue of the digestive tract and prevent malnutrition due to decreased absorption. is there.
- the content of glutamic acid or the like in the composition is desirably 0.05 to 2.0% by mass.
- a long protein is used in the amino acid compound, and the protein contains at least one kind of milk protein or vegetable protein.
- the composition lOOkcal contains 4.0 g or more, more preferably 5.0 g or more of protein.
- the copper content is 0.15 mg or less, and the mass ratio of zinc to copper is 10 to 25, preferably 10 to 20, more preferably 13 to 20, particularly preferably 15 to 18. In this case, it is more preferable that the zinc content is 1.5 mg or more and the copper content is 0.075 to 0.15 mg. This is a feature derived from the finding that high copper content inhibits zinc absorption.
- Yarn and adult product Contains at least 0.30mg of vitamin B1 and at least 0.25mg of vitamin B2 per lOOkcal. This is an application of efficient energy production by adding vitamin Bl, which is necessary for energy production of carbohydrates, and vitamin B2, which is necessary for energy production from lipid.
- the composition lOOkcal contains 1.5 to 3.0 mg of zinc, 0.075 to 0.15 mg of copper, and 165 to 385 mg of sodium per lOOkcal of the composition. More preferably, the composition lOOkcal contains 1.8 to 3.0 mg of zinc, 0.09 to 0.12 mg of copper, and 185 to 385 mg of sodium.
- the amount of vitamin B1 0.4 to 2 mg It is desirable to contain 0.25-2.0 mg of Tamine B2.
- the energy source of the total enteral nutrition composition of the present invention is protein, carbohydrate, and fat.
- the ratio of energy supplied by proteins, sugars and fats is preferably adjusted in the range of 10 to 40% from proteins, carbohydrate power 40 to 80% and fat to 10 to 40%.
- the protein is preferably contained in an amount of 4.0 g or more, more preferably 5.0 g or more per lOOkcal of the composition.
- Protein sources include acid casein, sodium caseinate, casein calcium, whey whey protein, fish protein, egg protein, and animal proteins such as these hydrolysates, soy protein, wheat protein, and corn. Any of these proteins and vegetable proteins such as these hydrolysates can be used.
- the ratio should be 4: 1 to 1: 4. It is desirable to include glutamine peptide and soy protein or its hydrolyzate as proteins. Furthermore, it is desirable that the total glutamine in the protein is at least 0.6 g per composition lOOkcal. Particularly preferred is a ratio of daltamine or glutamine peptide to soy protein or a hydrolyzate thereof: 1: 1 to 1: 4.
- Animal and vegetable absorbable fats can be used as the fat source.
- a medium chain fatty acid oil containing at least 35% by mass of fat and having a mass ratio of ⁇ 3 fatty acid to ⁇ 6 fatty acid in the fat of 1:10 to 1: 1 is preferable. Further, it is desirable that the medium-chain fatty acid triglyceride is 40 to 65% by mass in the fat and the mass ratio of ⁇ 3 fatty acid to ⁇ 6 fatty acid in the fat is 1: 4 to 1: 1.
- Medium chain fatty acids are fatty acids with 6 to 12 carbon atoms, and digestion and absorption are fast, so they are suitable as a therapeutic food for elderly and hospitalized patients!
- sugar source dextrin, oligosaccharide, sucrose, glucose, fructose and the like are used alone or in combination.
- the protein contains essential amino acids to further enhance nutritional value.
- Certain leucine, isoleucine, norin, threonine, lysine, methionine, phenylalanin, and tributophane are added as needed.
- minerals calcium, iron, phosphorus, magnesium, potassium, iodine, mangan, selenium, chromium, molybdenum, etc. are added as needed to the specially mentioned sodium, zinc, and copper. .
- the comprehensive enteral nutrition composition of the present invention is a treatment or prevention of protein 'energy undernutrition (PEM) in human, prevention of pressure ulcer, improvement of blood albumin level, improvement of albumin globulin ratio. , Improved reduced sodium content, improved hemoglobin level, improved hematocrit level, improved blood and in vivo mineral balance, increased zinc content, increased peripheral lymphocyte count! ], There are significant effects such as increased function of the gastrointestinal epithelium.
- PEM protein 'energy undernutrition
- a purified animal protein, plant protein, or a combination thereof is used as a protein source.
- a suitable ratio of animal protein to plant protein is 1: 4 to 4: 1.
- the presence of abundant glutamine which is attracting attention as an immunonutrition material, has a good systemic and intestinal immunity in humans.
- purified dartamine such as ara-glutglutamine glycylglutamine.
- the total amount of glutamine in the composition of the present invention is desirably 0.6 g or more per lOOkcal.
- glutamic acid, dipeptide or tripeptide containing glutamic acid, 5 'nucleotide, or salts thereof used in the present invention include, but are not limited to, the following. These are free glutamic acid, L-glutamic acid, dipeptidic (gal-glutamine) and tripeptides containing glutamic acid, 5'-inosinic acid or their sodium, potassium, calcium, and magnesium salts. Particularly preferred are sodium glutamate and 5'-sodium inosinate.
- the fat used in the total enteral nutrition composition of the present invention may be any fat source that can be ingested by humans.
- a high rate of energy supply is essential, medium-chain fatty acid triglycerides, medium-chain fatty acid diglycerides, and medium-chain fatty acids with absorption rates from the intestinal tract comparable to glucose and high energy production rates are included in the structure.
- Fat containing is recommended. It also contains omega-3 fatty acids such as eicosapentaenoic acid and linolenic acid, which have anti-inflammatory effects, and these fats are essential, such as patients with inflammation other than the gastrointestinal tract and humans who need inflammation prevention. Requires an active salary.
- the total enteral nutrition composition of the present invention contains at least 35% by weight of total chain fatty acid oil, and the mass ratio of ⁇ 3 fatty acid: ⁇ 6 fatty acid in the fat is 1:10 to 1 : 1 is preferable.
- the required amount of minerals is determined based on the Japanese dietary intake standards.
- the total enteral nutrition composition of the present invention has fortified sodium.
- the sodium source is not particularly limited as long as it is ingested or fed by humans, but sodium citrate and sodium phosphate are used as the main sodium sources in order to prevent protein precipitation by salting out.
- the effectiveness is shown when the sodium content is 165 mg or more per lOOkcal. Particularly, it has a remarkable effect at 185 to 385 mg per lOOkcal. Furthermore, it is preferable that it is 200-385 mg.
- Zinc which is greatly involved in the functions and structures of many enzymes in the body, is insufficient for humans with low nutritional status. Zinc supplementation increases blood zinc levels and is particularly useful for patients with or at risk for pressure ulcer wounds. Furthermore, since zinc absorption competes with copper, which is a divalent ion, it is necessary to mix the copper and zinc blending ratio and copper content so that they are advantageous for zinc absorption.
- the total enteral nutrition composition of the present invention At least 1.5 mg of lead, preferably 1.5-3.0 mg, and 0.075-0.15 mg of copper are blended, and the weight ratio of zinc to copper is 10-25, preferably 13-20, particularly preferably 15-18, most preferably 15.
- Vitamins are important as coenzymes essential for many biological activities such as energy production, protein metabolism, and maintenance of physiological functions of skin and mucous membranes. However, the amount to be formulated for undernourished humans has been fully studied so far.
- the total enteral nutrition composition of the present invention contains at least 0.30 mg vitamin B1, at least 0.25 mg vitamin B2, at least 0.3 mg vitamin B6, and at least 1.0 g piotin per lOOkcal.
- the most effective formulation is 0.4-2.0 mg vitamin B1 per lOOkcal, 0.25-2.0 mg B2, 0.5-2.0 mg vitamin B6, and 1.0-10 g piotin.
- vitamin B12 having anti-inflammatory action, antioxidant action and anti-decubitus action, folic acid, ⁇ -strength rotin, vitamin C and the like are added.
- vitamin B12 per lOOkcal of the total abdominal nutrition composition of the present invention, for example, vitamin B12 is 0.20 to 0.70 g, folic acid is 20 to 80 g, j8-power rotin is 100 to 450 ⁇ g, and vitamin C is 10 to 70 mg. Blend. All these vitamins can be derived from any raw material that can be ingested by humans.
- the general enteral nutrition composition of the present invention can be added with a suitable flavor and non-calorie sweetener such as aspartame.
- a suitable flavor and non-calorie sweetener such as aspartame.
- ingredients such as indigestible dietary fiber for promoting defecation and, in some cases, pharmaceuticals to be administered orally are added as necessary within the range that does not hinder the function of the total enteral nutrition composition of the present invention.
- Caro can be.
- the total enteral nutrition composition of the present invention is provided to humans with reduced nutritional status.
- protein / energy undernutrition (PEM) hypoalbuminemia, hyponatremia, zinc It is particularly effective for humans suffering from deficiency, anemia, decreased hemoglobin and hematocrit levels, pressure ulcers or wounds, and decreased immune capacity. Therefore, the total enteral nutrition composition of the present invention makes a great contribution to these people who have had no effective composition so far.
- composition 1 Preparation of total enteral nutrition composition (Composition 1)
- the nutrient composition [Table 1] was assembled.
- [Table 2] shows the raw material composition table of the liquid material for realizing this.
- sodium raw materials, protein raw materials and emulsifiers are blended according to the raw material blending table, and the pressure of the high-pressure emulsifier is set to 500-l, multiples of OOO KZM 2
- a liquid integrated enteral nutrition composition was prepared by carrying out a mulch emulsification step. That is, a good emulsion was prepared by repeating high-pressure emulsification of raw material and water using a high-pressure emulsifier.
- the ratio of animal protein to vegetable protein was 1: 1.5.
- the ratio of glutamine peptide to soy protein or hydrolyzate was 1: 1.4, and the ratio of ⁇ 3-fatty acid: ⁇ 6-fatty acid in the fatty acid yarn was 1: 3.
- This was filled into an aluminum bag using a normal filling machine, placed in a retort sterilizer, and sterilized under normal conditions. Even after one year, all components were stable and the viscosity was 9 mPa ⁇ s (25 ° C). [0027] [Table 1]
- composition 2 Preparation of total enteral nutrition composition (Composition 2)
- the nutrient composition shown in [Table 3] was assembled in the same manner as in Example 1.
- [Table 4] shows the raw material composition table of the liquid material for realizing this.
- the sodium raw material, protein raw material, and emulsifier were combined, and the pressure of the high-pressure emulsifier was set to 5.
- a plurality of emulsification steps were performed at 00 to 1,000 kgZcm 2 to prepare a liquid integrated enteral nutrition composition. That is, a good emulsion was prepared by repeating high-pressure emulsification of raw material and water using a high-pressure emulsifier.
- the ratio of animal protein to vegetable protein was 1: 2.
- the ratio of glutamine peptide to soy protein hydrolyzate was 3: 1, and the ratio of ⁇ 3-fatty acid: ⁇ 6-fatty acid in the fatty acid composition was 1: 1.
- composition 3 Preparation of total enteral nutrition composition (Composition 3)
- the nutrient composition shown in [Table 5] was assembled in the same manner as in Example 1.
- [Table 6] shows the amount of raw material blended to realize this.
- Example 1 with sodium raw material
- the protein raw material and the emulsifier were combined, and the emulsification step was performed a plurality of times by setting the pressure of the high-pressure emulsifier to 500 to 1000 kg, cm 2 to prepare a liquid general enteral nutrition composition. That is, a good emulsion was prepared by repeating high-pressure emulsification of raw material and water using a high-pressure emulsifier. This was filled into an aluminum bag using a normal filling machine, placed in a retort sterilizer, and sterilized under normal conditions. All components of this liquid were stable even after one year, and the viscosity was 10 mPa ⁇ s (25 ° C).
- Example 1 As shown in Table 7, in the blood test, total protein and albumin increased in Example 1 (A), and recovery of low nutritional power was revealed. On the other hand, the group receiving the commercial nutritional product (C) was delayed in recovery of nutritional status. The test solution (B) was found to be more effective than (C), but the results were inferior to those of the product (A) of the present invention. Furthermore, as a result of measuring minerals in the blood, Example 1 has a high value for iron, which is a representative of trace elements such as sodium and potassium as well as zinc and copper, and prevents in vitro loss of the administered minerals. The effect to do was recognized. Therefore, iron elevation is also effective against anemia and pressure ulcers, considering the high hemoglobin level in the blood.
- the comprehensive enteral nutrition composition of the present invention is effective for the prevention of protein / energy undernutrition (PEM) humans by preventing the decrease in absorption caused by the addition of glutamic acid and 5'-nucleotide.
- PEM protein / energy undernutrition
- the composition of the present invention contains a high concentration of sodium, it is useful for the treatment or prevention of hyponatremia.
- the composition of the present invention contains a high concentration of zinc it is used for the treatment or prevention of patients who are deficient in zinc.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
明 細 書 Specification
総合経腸栄養組成物 Total enteral nutrition composition
技術分野 Technical field
[0001] 本発明は新規な栄養組成物、より詳しくは、高齢者、入院患者などの栄養補給を必 要とし、消化管に器質的変化や障害がなぐたんぱく質の形態の窒素源を栄養素と して利用しうるヒトに対する総合経腸栄養組成物に関する。すなわち消化管に炎症、 壊死、切除、運動麻痺、ィレウス等の症状がなぐ加齢や低栄養状態に陥ったこと等 により消化吸収が減弱した状態の時に、たんぱく質、脂肪、ビタミン、ミネラル等を効 率よく吸収、補給させ、栄養状態を回復しうる総合経腸栄養組成物に関する。 [0001] The present invention requires a novel nutritional composition, more specifically, nutritional support for the elderly, hospitalized patients, and the like, and a nitrogen source in the form of a protein that is free from organic changes and disorders in the digestive tract is a nutrient. The present invention relates to a general enteral nutrition composition for humans that can be used. In other words, proteins, fats, vitamins, minerals, etc. are effective when digestive absorption is attenuated due to aging or undernutrition, etc., without inflammation, necrosis, excision, motor paralysis, ileus, etc. The present invention relates to a comprehensive enteral nutrition composition that can be absorbed and replenished efficiently and restore nutritional status.
背景技術 Background art
[0002] 近年、高齢入院患者、高齢の在宅療養者で栄養状態の悪ィ匕が懸念されて ヽる。低 栄養のなかでも特にたんぱく質、エネルギーの欠乏が複合して生じる栄養失調は、 たんぱく質 'エネルギー低栄養(Protein Energy Malnutrition ;PEM)と呼ばれ、この状 態に対しては効率のよい栄養補給の方法の重要性が認識されている。平成 7〜10 年の「高齢者の栄養管理サービスに関する研究」 (主任研究者:松田朗ほか 99年厚生 省報告)では、栄養指標である血清アルブミン値が 3.5gZdL以下の PEMリスク者は 、高齢入院患者の約 4割、在宅訪問患者の約 3割で観察された。食事摂取量の低下 など力 適切なたんぱく質やエネルギーの供給不足が、重篤な低栄養状態を招き、 この結果、免疫低下による感染症、筋力の低下、寝たきりの状態がおこり、最終的に 在院日数の延長、医療費の増大の原因につながつている。寝たきりの場合には褥瘡 を発症することが多いが、褥瘡発生に関する因子として、エネルギー摂取不足、たん ばく量摂取不足、体内におけるたんぱく合成の障害、脂肪摂取不良、亜鉛など微量 元素の欠乏などが原因としてあげられている。また、高齢者の褥瘡発生に関与する 特徴的な因子として、血管障害など複数の合併症、食欲不振、低栄養からの免疫能 低下があるといわれている (臨床栄養 103卷、 4号、 424〜431頁、 2003年)。 [0002] In recent years, there has been concern about poor nutritional status among elderly inpatients and elderly home caregivers. Among malnutrition, malnutrition caused by a combination of protein and energy deficiency is called protein 'protein energy malnutrition (PEM). The importance of is recognized. According to the “Research on Nutrition Management Services for the Elderly” between 1995 and 1998 (Principal investigator: Akira Matsuda et al., 1999 Ministry of Health and Welfare Report), those with PEM risk whose serum albumin level is less than 3.5 gZdL It was observed in about 40% of hospitalized patients and about 30% of home-visit patients. Reduced food intake, etc.Insufficient supply of appropriate protein and energy leads to severe malnutrition, resulting in infectious diseases due to decreased immunity, muscle weakness, and bedridden conditions. This has led to an increase in the number of days and medical costs. Bedriddens often develop pressure ulcers, but factors related to pressure ulcers are caused by factors such as insufficient energy intake, insufficient protein intake, impaired protein synthesis in the body, poor fat intake, and lack of trace elements such as zinc. It is given as. In addition, it is said that there are multiple complications such as vascular disorders, loss of appetite, and reduced immune capacity from undernutrition as characteristic factors involved in the development of pressure ulcers in the elderly (Clinical Nutrition 103, 4, 424 ~ 431 pages, 2003).
[0003] 栄養補給を必要とする対象者のための、たんぱく質、脂質、糖質、ビタミン、ミネラ ルを総合的に含む経腸栄養組成物が知られている (特許文献 1)。これは、これのみ で栄養管理を可能とする栄養組成物であって、その配合組成中のたんぱく質原料に 乳たんぱく質および大豆たんぱく質を特定の割合で含むことと、脂質中の ω 3系脂肪 酸と ω 6系脂肪酸を特定の比率で含むことを特徴としている。また、たんぱく質、脂質 、糖質、乳化剤および水力ゝらなり、浸透圧およびアミノ酸スコアを特定した総合経腸 栄養剤が知られて ヽる (特許文献 2)。 [0003] Enteral nutritional compositions that comprehensively include proteins, lipids, carbohydrates, vitamins, and minerals for subjects who need nutritional supplementation are known (Patent Document 1). This is only this A nutritional composition that enables nutritional management at the same time, including a specific proportion of milk protein and soy protein in the protein raw material in the composition, and omega-3 fatty acid and omega-6 fatty acid in the lipid It is characterized by inclusion at a specific ratio. Also known is a general enteral nutritional product that is made up of proteins, lipids, carbohydrates, emulsifiers, and hydraulics, and that specifies osmotic pressure and amino acid score (Patent Document 2).
[0004] 特に高齢者や高度な低栄養のヒトでは胃の容量も大きくなぐ摂取できる食物量が 限られる。したがって、摂取量当たりのカロリーが高ぐし力も各栄養成分をバランスよ く含み、かつビタミン、ミネラルなどの成分が高濃度に入っている経腸栄養組成物は 重要である。このため、経腸栄養組成物 lOOmLで lOOkcal摂取できるものが巿販さ れており、その需要は今後も増大すると予測される。 [0004] In particular, the amount of food that can be consumed with a large stomach capacity is limited in elderly people and highly undernourished humans. Therefore, enteral nutritional compositions that contain a high balance of nutritional components and high concentrations of vitamins, minerals, and other nutrients are important. For this reason, entero nutritional composition lOOmL that can be ingested by lOOkcal is sold on the market, and the demand is expected to increase in the future.
[0005] し力し現状においては、栄養指標である血清アルブミン値を改善し、血中の銅、亜 鉛、ナトリウム等の濃度を適性に保ち、かつ褥瘡の改善において効果のある経腸栄 養剤は未だ知られていない。また、精製された純度の高いたんぱく質、脂質を多く配 合し、それらの生体内でのエネルギー産生を円滑にするためのビタミン類を適正に 含ませるという総合的な観点で、必要成分を適切に配合した総合経腸栄養組成物は これまで供給されていない。特に、たんぱく質を多く含む栄養組成物に対してナトリウ ム含量を増やすことは、これまでたんぱく質沈殿 (塩祈)が生じることから限界があった 。しかし、高齢者の場合には低ナトリウム血症を起こす場合があるので、高工ネルギ 一総合経腸栄養組成物において、たんぱく質含量と同時にナトリウム含量を高めるこ とは極めて重要である。 [0005] At present, enteral nutrition is effective in improving serum albumin levels, which are nutritional indicators, maintaining appropriate concentrations of copper, zinc, sodium, etc. in blood and improving pressure ulcers. The drug is not yet known. In addition, the necessary ingredients are appropriately selected from the comprehensive viewpoint of combining a large amount of purified proteins and lipids with high purity and appropriately containing vitamins for smooth energy production in vivo. The combined total enteral nutritional composition has not been supplied so far. In particular, increasing the sodium content of nutritional compositions rich in protein has been limited in the past because of protein precipitation (salt prayer). However, since it may cause hyponatremia in the elderly, it is extremely important to increase the sodium content at the same time as the protein content in the Takagi Nerghi Total Enteral Nutrient Composition.
[0006] 一方、経腸栄養法で栄養管理をする場合には、消化吸収低下により十分な経腸栄 養が実施できず、患者の栄養状態の低下が深刻な問題となって 、る。 [0006] On the other hand, when nutritional management is performed using the enteral nutrition method, sufficient enteral nutrition cannot be performed due to a decrease in digestion and absorption, and the reduction of the nutritional status of patients is a serious problem.
[0007] グルタミン酸は以前からうま味成分として食物に調味料として使用されている。最近 の研究により、グルタミン酸は食物の胃力 の排出を促進し、消化管に好影響を与え ることが明ら力となってきた (非特許文献 1)。グルタミン酸や 5'—ヌクレオチドが、大き な手術後のような消化管に器質的な障害がある場合において、下痢を軽減する効果 のあることが報告されている(特許文献 3)。また、グルタミン酸や 5'—ヌクレオチドは、 器質的障害が見られない患者の腹部痛、胃もたれ、胸やけ等の機能性胃腸症、胃 食道逆流の上部消化管の機能性胃腸症、胃食道逆流症に有効であることが開示さ れている(特許文献 4)。 [0007] Glutamic acid has long been used as a seasoning in foods as an umami component. Recent research has revealed that glutamic acid promotes the excretion of food gastric power and has a positive effect on the gastrointestinal tract (Non-patent Document 1). It has been reported that glutamic acid and 5′-nucleotide are effective in reducing diarrhea when there is an organic disorder in the digestive tract, such as after a large operation (Patent Document 3). Glutamate and 5'-nucleotide are also useful for functional gastroenteropathy such as abdominal pain, stomach sag, heartburn, etc. It is disclosed that it is effective for functional gastroenteropathy and gastroesophageal reflux disease in the upper gastrointestinal tract of esophageal reflux (Patent Document 4).
[0008] 一方、消化吸収の低下のうちでも単なる加齢や低栄養状態に陥ったこと等により、 消化吸収が減弱した状態が存在する。このときの栄養補給の窒素源としては、消化 吸収に優れる動物や植物由来のたんぱく質が使用される。し力しながらこのときに栄 養状態を回復できる有効な栄養組成物は ヽまだ発見されて ヽな ヽ。 [0008] On the other hand, there is a state in which digestion and absorption are attenuated due to mere aging, under-nutrition, etc. among the decrease in digestion and absorption. As a nitrogen source for supplementation at this time, proteins derived from animals and plants that excel in digestion and absorption are used. However, an effective nutritional composition that can restore the nutritional state at this time is still uncovered.
特許文献 1:特許第 3102645号公報 Patent Document 1: Japanese Patent No. 3102645
特許文献 2:特開 2004-51494公報 Patent Document 2: JP 2004-51494 A
特許文献 3: WO2006/001492 Patent Document 3: WO2006 / 001492
特許文献 4: WO2006/030980 Patent Document 4: WO2006 / 030980
非特許文献 1 Gastroenterology: 130卷、 4号、 Supple 2、 A246、 2006年 Non-Patent Literature 1 Gastroenterology: 130 卷, No. 4, Supple 2, A246, 2006
発明の開示 Disclosure of the invention
発明が解決しょうとする課題 Problems to be solved by the invention
[0009] 本発明の課題は、高齢者、入院患者のように、食事によって十分な栄養摂取ができ な 、ヒトに対して、それのみで必要とされる栄養を全て供給できる改善された総合経 腸栄養組成物を供給することである。詳しくは、栄養指標である血清アルブミン値の 改善および褥瘡の改善、さらには血中ミネラルバランスの改善に効果があり、かつ低 栄養状態の回復に顕著な効果を奏する、たんぱく質、脂肪、糖質、ビタミン、ミネラル 、特に亜鉛および銅を適正に配合し、この上グルタミン酸や 5 '—ヌクレオチドを配合 することで腸管の状態を高め吸収能力を高めた総合経腸栄養組成物を提供すること である。さらには、窒素供給源として用いるたんぱく質の配含量を最大限に高めても 、たんぱく質が沈殿を起こさないようにナトリウムを配合し、ビタミン Bl、ビタミン B2を 高含量とした、効率よい栄養状態の回復、低栄養状態の予防、褥瘡の改善および予 防効果のある新規な総合経腸栄養組成物を提供することである。 [0009] An object of the present invention is to provide an improved comprehensive system capable of supplying all the nutrients necessary for a person who cannot receive sufficient nutrition through meals, such as the elderly and hospitalized patients. Providing an enteral nutritional composition. Specifically, proteins, fats, and carbohydrates that are effective in improving serum albumin levels and pressure ulcers, which are nutritional indicators, and in improving blood mineral balance and remarkably improving the recovery of undernutrition. The aim is to provide a comprehensive enteral nutritional composition containing vitamins and minerals, especially zinc and copper, and also containing glutamic acid and 5'-nucleotide to improve the state of the intestinal tract and enhance absorption capacity. Furthermore, even if the protein content used as a nitrogen source is maximized, sodium is added so that the protein does not precipitate, and vitamin B and vitamin B2 are contained in a high content. It is to provide a novel integrated enteral nutritional composition that is effective in preventing malnutrition, improving pressure ulcers, and preventing it.
課題を解決するための手段 Means for solving the problem
[0010] 本発明の総合経腸栄養組成物は、消化管の器質的障害を有しないヒトに使用する ものであって、たんぱく質、糖質、脂肪、ミネラル、ビタミンを含み、以下の特徴を総合 的に組み合わせることによって所期の目的を達成するものである。 (1)組成物 lOOkcalあたり、ナトリウムを 165mg以上含有し、グルタミン酸、グルタミン 酸を含むジペプチド若しくはトリペプチド、 5' ヌクレオチド又はそれらの塩力 選ば れる少なくとも一種を含む。ナトリウムの欠乏を防止するためには、高濃度のナトリウム を含有させる必要がある。高濃度のナトリウムは、たんぱく質を高濃度とした場合、塩 祈によるたんぱく質の沈殿を起こすが、この問題は、主たるナトリウム源として燐酸ナ トリウムおよびクェン酸ナトリウム等を用いることによって防止できる。グルタミン酸、グ ルタミン酸を含むジペプチド若しくはトリペプチド、 5' ヌクレオチド又はそれらの塩 を配合することによって、消化管の上皮組織の状態を高め、吸収低下による低栄養 を防止できるという知見を応用したものである。組成物中のグルタミン酸等の含有量 は 0.05〜2.0質量%とすることが望ましい。 [0010] The total enteral nutrition composition of the present invention is used for humans who do not have an organic disorder of the gastrointestinal tract, and includes proteins, carbohydrates, fats, minerals, and vitamins, and has the following characteristics. By combining them together, the intended purpose is achieved. (1) Composition lOOkcal contains 165 mg or more of sodium, and contains at least one selected from glutamic acid, dipeptides or tripeptides containing glutamic acid, 5 ′ nucleotides or their salt strength. In order to prevent sodium deficiency, it is necessary to contain a high concentration of sodium. High concentrations of sodium cause protein precipitation due to salt prayer when the protein concentration is high, but this problem can be prevented by using sodium phosphate, sodium citrate, etc. as the main sodium source. Applying the knowledge that glutamic acid, dipeptide or tripeptide containing glutamic acid, 5 'nucleotide or their salts can be added to enhance the state of epithelial tissue of the digestive tract and prevent malnutrition due to decreased absorption. is there. The content of glutamic acid or the like in the composition is desirably 0.05 to 2.0% by mass.
(2)窒素供給源としてはアミノ酸配合物ではなぐたんぱく質を用い、該たんぱく質 は乳たんぱく質または植物性たんぱく質の少なくとも一種以上を含有する。好ましく は、組成物 lOOkcalあたり、たんぱく質を 4.0g以上、より好ましくは 5.0g以上含有する (2) As a nitrogen supply source, a long protein is used in the amino acid compound, and the protein contains at least one kind of milk protein or vegetable protein. Preferably, the composition lOOkcal contains 4.0 g or more, more preferably 5.0 g or more of protein.
(3)組成物 lOOkcalあたり、銅含量を 0.15mg以下とし、亜鉛と銅の質量比を 10〜2 5、好ましくは 10〜20、さら好ましくは 13〜20、特に好ましくは 15〜18とする。この 場合、亜鉛含量を 1.5mg以上とし、銅含量を 0.075〜0.15mgとすることがなお好まし い。これは、銅の含有量が高いと亜鉛の吸収が阻害されるという知見に基づいて導 かれる特徴点である。 (3) Composition per lOOkcal, the copper content is 0.15 mg or less, and the mass ratio of zinc to copper is 10 to 25, preferably 10 to 20, more preferably 13 to 20, particularly preferably 15 to 18. In this case, it is more preferable that the zinc content is 1.5 mg or more and the copper content is 0.075 to 0.15 mg. This is a feature derived from the finding that high copper content inhibits zinc absorption.
(4)糸且成物 lOOkcalあたり、ビタミン B1を少なくとも 0.30mgおよびビタミン B2を少な くとも 0.25mg含む。これは、糖質力ものエネルギー産生に必要なビタミン Bl、脂質か らのエネルギー産生に必要なビタミン B2を高濃度に入れることによって、エネノレギー 産生を効率よく出来ることを応用したものである。 (4) Yarn and adult product Contains at least 0.30mg of vitamin B1 and at least 0.25mg of vitamin B2 per lOOkcal. This is an application of efficient energy production by adding vitamin Bl, which is necessary for energy production of carbohydrates, and vitamin B2, which is necessary for energy production from lipid.
さらに詳しく説明すれば、組成物 lOOkcalあたり、亜鉛を 1.5〜3.0mg、銅を 0.075 〜0.15mg、ナトリウムを 165〜385mg含有することが望ましい。さらに好ましくは、組 成物 lOOkcalあたり、亜鉛を 1.8〜3.0mg、銅を 0.09〜0.12mg、ナトリウムを 185〜3 85mg含有する。また、糖質、脂肪の体内での燃焼を助長するために、これまで既知 のビタミンの使用量よりも高めて、糸且成物 lOOkcalあたり、ビタミン B1を 0.4〜2mg、ビ タミン B2を 0.25〜2.0mg含有することが望ましい。その他のビタミンとして、ビタミン B 6を少なくとも 0.3mg、好ましくは 0.5〜2.0mg、ピオチンを少なくとも 1.0 g、好ましく は 1.0〜10 g配合することが望ましい。さらに lOOkcalあたりビタミン B12を 0.20〜 0.70 μ g、葉酸を 20〜80 g、 j8—力 Pチンを 100〜450 μ g、ヒ、、タミン Cを 10〜70m g添加することがより良 、効果を与える。 More specifically, it is desirable to contain 1.5 to 3.0 mg of zinc, 0.075 to 0.15 mg of copper, and 165 to 385 mg of sodium per lOOkcal of the composition. More preferably, the composition lOOkcal contains 1.8 to 3.0 mg of zinc, 0.09 to 0.12 mg of copper, and 185 to 385 mg of sodium. In addition, in order to promote the burning of carbohydrates and fats in the body, the amount of vitamin B1 0.4 to 2 mg It is desirable to contain 0.25-2.0 mg of Tamine B2. As other vitamins, it is desirable to mix at least 0.3 mg, preferably 0.5 to 2.0 mg of vitamin B6 and at least 1.0 g, preferably 1.0 to 10 g of piotin. In addition, 0.20 to 0.70 μg of vitamin B12 per lOOkcal, 20 to 80 g of folic acid, j8—force 100 to 450 μg of P-tin, 10 to 70 mg of hin and tamin C is better and more effective. give.
[0012] 本発明の総合経腸栄養組成物のエネルギー源は、たんぱく質、糖質、脂肪である 。たんぱく質、糖質、脂肪によって供給されるエネルギーの比率は、たんぱく質から 1 0〜40%、糖質力 40〜80%、脂肪から 10〜40%の範囲で調節するのが好ましい 。たんぱく質は、組成物 lOOkcalあたり、好ましくは 4.0g以上、より好ましくは 5.0g以 上含有させる。たんぱく源としては、酸カゼイン、カゼインナトリウム、カゼインカルシゥ ム、乳清ホエーたんぱく質、魚肉たんぱく質、卵たんぱく質などやこれらの加水分解 物を例とする動物性たんぱく質、および大豆たんぱく質、小麦たんぱく質、とうもろこ したんぱく質などやこれらの加水分解物を例とする植物性たんぱく質の如何なるもの も利用できる。動物性たんぱく質と植物性たんぱく質を混合使用し、その比率を 4 : 1 〜1 : 4とすることが望ましい。たんぱく質としてグルタミンペプチドと、大豆たんぱく質 あるいはその加水分解物を含むことが望ましい。さらに、組成物 lOOkcalあたり、たん ばく質中の総グルタミンが少なくとも 0.6gであることが望ましい。特に好ましくは、ダル タミンあるいはグルタミンペプチドと、大豆たんぱく質あるいはこの加水分解物の比率 カ : 1〜1 : 4でぁる。 [0012] The energy source of the total enteral nutrition composition of the present invention is protein, carbohydrate, and fat. The ratio of energy supplied by proteins, sugars and fats is preferably adjusted in the range of 10 to 40% from proteins, carbohydrate power 40 to 80% and fat to 10 to 40%. The protein is preferably contained in an amount of 4.0 g or more, more preferably 5.0 g or more per lOOkcal of the composition. Protein sources include acid casein, sodium caseinate, casein calcium, whey whey protein, fish protein, egg protein, and animal proteins such as these hydrolysates, soy protein, wheat protein, and corn. Any of these proteins and vegetable proteins such as these hydrolysates can be used. It is desirable to use a mixture of animal protein and vegetable protein, and the ratio should be 4: 1 to 1: 4. It is desirable to include glutamine peptide and soy protein or its hydrolyzate as proteins. Furthermore, it is desirable that the total glutamine in the protein is at least 0.6 g per composition lOOkcal. Particularly preferred is a ratio of daltamine or glutamine peptide to soy protein or a hydrolyzate thereof: 1: 1 to 1: 4.
[0013] 脂肪源としては、動物性および植物性の吸収可能な脂肪が使用できる。中鎖脂肪 酸油を少なくとも脂肪中 35質量%含み、かつ脂肪中の ω 3系脂肪酸: ω 6系脂肪酸 の質量比が1 : 10〜1 : 1でぁるものが好ましぃ。さらに、中鎖脂肪酸トリグリセリドが脂 肪中 40〜65質量%でかつ脂肪中の ω 3系脂肪酸: ω 6系脂肪酸の質量比が 1 : 4〜 1 : 1であることが望ましい。中鎖脂肪酸は炭素数 6〜12の脂肪酸であり、消化吸収が 早 、ので高齢者、入院患者の治療食として適して!/、る。 [0013] Animal and vegetable absorbable fats can be used as the fat source. A medium chain fatty acid oil containing at least 35% by mass of fat and having a mass ratio of ω 3 fatty acid to ω 6 fatty acid in the fat of 1:10 to 1: 1 is preferable. Further, it is desirable that the medium-chain fatty acid triglyceride is 40 to 65% by mass in the fat and the mass ratio of ω3 fatty acid to ω6 fatty acid in the fat is 1: 4 to 1: 1. Medium chain fatty acids are fatty acids with 6 to 12 carbon atoms, and digestion and absorption are fast, so they are suitable as a therapeutic food for elderly and hospitalized patients!
[0014] 糖質源としては、デキストリン、オリゴ糖、蔗糖、グルコース、果糖などを単独で若しく は糸且み合わせて用いる。 [0014] As the sugar source, dextrin, oligosaccharide, sucrose, glucose, fructose and the like are used alone or in combination.
[0015] 上記の成分のほかに、栄養価をさらに高めるためにたんぱく質に、必須アミノ酸で あるロイシン、イソロイシン、ノ リン、スレオニン、リジン、メチォニン、フエ二ルァラニン 、トリブトファンを必要に応じて添加する。また、ミネラルとしては、先に特記したナトリ ゥム、亜鉛、銅のほ力に、カルシウム、鉄、リン、マグネシウム、カリウム、ヨウ素、マン ガン、セレン、クロム、モリブデンなどを必要に応じて添加する。 [0015] In addition to the above ingredients, the protein contains essential amino acids to further enhance nutritional value. Certain leucine, isoleucine, norin, threonine, lysine, methionine, phenylalanin, and tributophane are added as needed. As minerals, calcium, iron, phosphorus, magnesium, potassium, iodine, mangan, selenium, chromium, molybdenum, etc. are added as needed to the specially mentioned sodium, zinc, and copper. .
発明の効果 The invention's effect
[0016] 本発明の総合経腸栄養組成物は、たんぱく質'エネルギー低栄養 (PEM)のヒトの治 療あるいは予防、褥瘡の予防'改善、血中のアルブミン値の改善、アルブミン グロ ブリン比の改善、低下したナトリウム含量の改善、ヘモグロビン値の改善、へマトクリツ ト値の改善、血中および生体内ミネラルバランスの改善、亜鉛含量の増加、末梢リン パ球数の増力!]、消化管上皮組織の機能上昇などの顕著な効果を奏する。 [0016] The comprehensive enteral nutrition composition of the present invention is a treatment or prevention of protein 'energy undernutrition (PEM) in human, prevention of pressure ulcer, improvement of blood albumin level, improvement of albumin globulin ratio. , Improved reduced sodium content, improved hemoglobin level, improved hematocrit level, improved blood and in vivo mineral balance, increased zinc content, increased peripheral lymphocyte count! ], There are significant effects such as increased function of the gastrointestinal epithelium.
発明を実施するための最良の形態 BEST MODE FOR CARRYING OUT THE INVENTION
[0017] 本発明の総合経腸栄養組成物では、精製された動物性たんぱく質、植物性たんぱ く質ある 、はこれらの組み合わせをたんばく源として用いる。特に脳血管障害のある ヒトまたは高脂血症のヒトには、栄養素バランスの 1つとして動物性たんぱく質と植物 性たんぱく質の比率を適当な範囲として摂取することが動脈硬化防止や血中脂肪低 下のために重要である。本発明の総合経腸栄養組成物では、動物性たんぱく質と植 物性たんぱく質の比率を 1 :4〜4: 1とすることが推奨される。さらに、免疫栄養素材と して注目されるグルタミンを豊富に含むとヒトの全身や腸管免疫状態がよいことも確認 され、必要な状況のヒトにはグルタミンあるいは小麦ダルテン加水分解物由来のダル タミンペプチド、さらにはァラ-ルグルタミンゃグリシルグルタミン等の精製されたダル タミンの配合が推奨される。本発明組成物中の総グルタミン量は、 lOOkcalあたり 0.6 g以上が望ましい。 [0017] In the total enteral nutrition composition of the present invention, a purified animal protein, plant protein, or a combination thereof is used as a protein source. In particular, for humans with cerebrovascular disorders or hyperlipidemic patients, taking a suitable ratio of animal protein to plant protein as a nutrient balance prevents arteriosclerosis and reduces blood fat. Is important for. In the total enteral nutrition composition of the present invention, it is recommended that the ratio of animal protein to plant protein is 1: 4 to 4: 1. Furthermore, it has been confirmed that the presence of abundant glutamine, which is attracting attention as an immunonutrition material, has a good systemic and intestinal immunity in humans. Furthermore, it is recommended to add purified dartamine such as ara-glutglutamine glycylglutamine. The total amount of glutamine in the composition of the present invention is desirably 0.6 g or more per lOOkcal.
[0018] 本発明に使用するグルタミン酸、グルタミン酸を含むジペプチド若しくはトリペプチド 、 5' ヌクレオチド又はそれらの塩としては次のものが例示される力 これに限定され るものではない。遊離のグルタミン酸、 L—グルタミン酸、グルタミン酸を含むジぺプチ ド (ァラ-ルグルタミン)やトリペプチド、 5'—イノシン酸又はそれらのナトリウム塩、カリ ゥム塩、カルシウム塩、マグネシウム塩である。特に好ましいのは、グルタミン酸ナトリ ゥム、 5'—イノシン酸ナトリウムである。腸管上皮細胞の良好な状態の保全、回復、す なわち上皮細胞のジァミンォキシダーゼ (DAO)活性の維持に対しては、適切なた んぱく質量の補給が必要であり、さらにグルタミン酸は上皮細胞の回復を促進する。 この腸管上皮の維持は、ひいては吸収効率の低下を防止する効果がある。この改善 維持効果には、適切な遊離グルタミン酸とたんぱく質総量の割合が重要であるとの 知見を得た。この割合 (遊離グルタミン酸:たんぱく質総量)は 1: 120〜1: 3が好まし い。 [0018] Examples of glutamic acid, dipeptide or tripeptide containing glutamic acid, 5 'nucleotide, or salts thereof used in the present invention include, but are not limited to, the following. These are free glutamic acid, L-glutamic acid, dipeptidic (gal-glutamine) and tripeptides containing glutamic acid, 5'-inosinic acid or their sodium, potassium, calcium, and magnesium salts. Particularly preferred are sodium glutamate and 5'-sodium inosinate. Preservation, recovery, and maintenance of the good state of intestinal epithelial cells In other words, maintenance of epithelial cell diaminoxidase (DAO) activity requires supplementation of the appropriate protein mass, and glutamate promotes epithelial cell recovery. This maintenance of the intestinal epithelium is effective in preventing a decrease in absorption efficiency. It was found that an appropriate ratio of free glutamic acid and total protein is important for this improvement and maintenance effect. This ratio (free glutamic acid: total protein) is preferably from 1: 120 to 1: 3.
[0019] 本発明の総合経腸栄養組成物に用いる脂肪は、ヒトが摂取できる脂肪源であれば よい。とくに、高率のエネルギー供給が必須の場合、グルコースに匹敵する腸管から の吸収速度を有し、エネルギー産生率が大きい中鎖脂肪酸トリグリセリド、中鎖脂肪 酸ジグリセリドゃ中鎖脂肪酸をその構造の中に含む脂肪が推奨される。また、抗炎症 作用を有するエイコサペンタエン酸ゃ aリノレン酸などの ω 3系脂肪酸を含むことも、 消化管以外に炎症を持った患者や炎症予防が必要なヒトなど、これらの脂肪が必須 なヒトには積極的な給与が必要である。本発明の総合経腸栄養組成物では、とく〖こ 中鎖脂肪酸油を総脂肪の 35質量%以上含み、かつ脂肪中の ω 3系脂肪酸: ω 6系 脂肪酸の質量比が 1: 10〜1: 1とすることが好ましい。 [0019] The fat used in the total enteral nutrition composition of the present invention may be any fat source that can be ingested by humans. In particular, when a high rate of energy supply is essential, medium-chain fatty acid triglycerides, medium-chain fatty acid diglycerides, and medium-chain fatty acids with absorption rates from the intestinal tract comparable to glucose and high energy production rates are included in the structure. Fat containing is recommended. It also contains omega-3 fatty acids such as eicosapentaenoic acid and linolenic acid, which have anti-inflammatory effects, and these fats are essential, such as patients with inflammation other than the gastrointestinal tract and humans who need inflammation prevention. Requires an active salary. The total enteral nutrition composition of the present invention contains at least 35% by weight of total chain fatty acid oil, and the mass ratio of ω 3 fatty acid: ω 6 fatty acid in the fat is 1:10 to 1 : 1 is preferable.
[0020] ミネラルの必要量は、 日本人の食事摂取基準を基本に定めることを原則とする。し かし、高齢者では摂取量が低下して低ナトリウム血症が問題となるため、本発明の総 合経腸栄養組成物ではナトリウムを強化した。ナトリウム源は、ヒトが摂取または給与 されるものであればよくその種類は問われないが、塩析によってたんぱく質を沈殿さ せないために、クェン酸ナトリウム、燐酸ナトリウムを主たるナトリウム源として用いる。 本発明にお 、ては、ナトリウム含量が lOOkcalあたり 165mg以上で有効性が示される 力 特に、 lOOkcalあたり 185〜385mgで著しい効果を有する。さらには 200〜385m gであることが好ましい。 [0020] In principle, the required amount of minerals is determined based on the Japanese dietary intake standards. However, since the intake is reduced in elderly people and hyponatremia becomes a problem, the total enteral nutrition composition of the present invention has fortified sodium. The sodium source is not particularly limited as long as it is ingested or fed by humans, but sodium citrate and sodium phosphate are used as the main sodium sources in order to prevent protein precipitation by salting out. In the present invention, the effectiveness is shown when the sodium content is 165 mg or more per lOOkcal. Particularly, it has a remarkable effect at 185 to 385 mg per lOOkcal. Furthermore, it is preferable that it is 200-385 mg.
[0021] 生体の多くの酵素の機能、構造に大きく関わる亜鉛は、栄養状態が低いヒトには不 足する。亜鉛の補給は、血中の亜鉛濃度を上昇させ、特に褥瘡など創傷をもつ患者 あるいはこのリスクのあるヒトに有用である。さらに亜鉛の吸収は 2価イオンである銅と 競合することから、銅と亜鉛の配合割合と銅の含有量を、亜鉛の吸収に有利なよう〖こ 配合する必要がある。本発明の総合経腸栄養組成物においては、 lOOkcalあたり亜 鉛を少なくとも 1.5mg、好ましくは 1.5〜3.0mg、銅を 0.075〜0.15mg配合し、亜鉛と 銅の質量比を 10〜25、好ましくは 13〜20、特に好ましくは 15〜18、最も好ましくは 15とすることにより、褥瘡などの創傷治癒を促進させる効果が得られる。さらに、栄養 補給が必要なヒトの炎症状態に応じて、抗酸ィ匕作用をもつ微量元素であるセレンを 1 OOkcalあたり 4.5〜18 μ g程度本品に添加することは有用である。 [0021] Zinc, which is greatly involved in the functions and structures of many enzymes in the body, is insufficient for humans with low nutritional status. Zinc supplementation increases blood zinc levels and is particularly useful for patients with or at risk for pressure ulcer wounds. Furthermore, since zinc absorption competes with copper, which is a divalent ion, it is necessary to mix the copper and zinc blending ratio and copper content so that they are advantageous for zinc absorption. In the total enteral nutrition composition of the present invention, At least 1.5 mg of lead, preferably 1.5-3.0 mg, and 0.075-0.15 mg of copper are blended, and the weight ratio of zinc to copper is 10-25, preferably 13-20, particularly preferably 15-18, most preferably 15. By doing, the effect which accelerates | stimulates wound healing, such as a pressure ulcer, is acquired. In addition, it is useful to add about 4.5-18 μg of selenium, a trace element with anti-acidic activity, to each product depending on the inflammatory condition of humans who need nutritional supplementation.
[0022] ビタミンは、エネルギー産生、たんぱく質代謝、皮膚や粘膜の生理機能保持などの 多くの生体活動に必須の補酵素として重要である。しかし、低栄養状態のヒトに対し て配合されるべき量の検討はこれまで十分になされて 、な 、。本発明の総合経腸栄 養組成物においては、 lOOkcalあたりビタミン B1を少なくとも 0.30mg、ビタミン B2を 少なくとも 0.25mg、ビタミン B6を少なくとも 0.3mg、ピオチンを少なくとも 1.0 g配合 する。さらに最も効果的な配合は、 lOOkcalあたりビタミン B1が 0.4〜2.0mg、 B2が 0. 25〜2.0mg、ビタミン B6が 0.5〜2.0mg、ピオチンが 1.0〜10 gである。さらに、そ の他のビタミンの添加が栄養状態の改善'維持、低栄養状態の予防、褥瘡の治療あ るいは予防、貧血の治療あるいは予防のために有効である。本発明の総合経腸栄養 組成物では、抗炎症作用、抗酸化作用、褥瘡防止作用のあるビタミン B12、葉酸、 β 一力ロチン、ビタミン Cなどを配合することが推奨される。具体的には、本発明の総合 経腹栄養組成物 lOOkcalあたり、例えばビタミン B12を 0.20〜0.70 g、葉酸を 20 〜80 g、 j8—力ロチンを 100〜450 μ g、ビタミン Cを 10〜70mg配合する。これらす ベての配合ビタミンはヒトが摂取できるものであればいずれの原材料でもよぐ由来等 が特定されるものではな 、。 [0022] Vitamins are important as coenzymes essential for many biological activities such as energy production, protein metabolism, and maintenance of physiological functions of skin and mucous membranes. However, the amount to be formulated for undernourished humans has been fully studied so far. The total enteral nutrition composition of the present invention contains at least 0.30 mg vitamin B1, at least 0.25 mg vitamin B2, at least 0.3 mg vitamin B6, and at least 1.0 g piotin per lOOkcal. The most effective formulation is 0.4-2.0 mg vitamin B1 per lOOkcal, 0.25-2.0 mg B2, 0.5-2.0 mg vitamin B6, and 1.0-10 g piotin. Furthermore, the addition of other vitamins is effective for improving or maintaining nutritional status, preventing malnutrition, treating or preventing pressure ulcers, and treating or preventing anemia. In the total enteral nutrition composition of the present invention, it is recommended that vitamin B12 having anti-inflammatory action, antioxidant action and anti-decubitus action, folic acid, β-strength rotin, vitamin C and the like are added. Specifically, per lOOkcal of the total abdominal nutrition composition of the present invention, for example, vitamin B12 is 0.20 to 0.70 g, folic acid is 20 to 80 g, j8-power rotin is 100 to 450 μg, and vitamin C is 10 to 70 mg. Blend. All these vitamins can be derived from any raw material that can be ingested by humans.
[0023] 本発明の総合経腸栄養組成物には、経口摂取を容易にするために、適当な香料、 アスパルテームなどのノンカロリー甘味料を加えることが可能である。さらに、排便促 進のための難消化性食物繊維などの成分、場合によっては経口投与される医薬品 なども、本発明の総合経腸栄養組成物の機能を妨げな ヽ範囲で必要に応じて添カロ することができる。 [0023] In order to facilitate oral intake, the general enteral nutrition composition of the present invention can be added with a suitable flavor and non-calorie sweetener such as aspartame. In addition, ingredients such as indigestible dietary fiber for promoting defecation and, in some cases, pharmaceuticals to be administered orally are added as necessary within the range that does not hinder the function of the total enteral nutrition composition of the present invention. Caro can be.
[0024] 低栄養状態のヒトは、経口摂取が困難なことが多くこの場合にはチューブを使って 経管による栄養補給が積極的に実施される。しかし、これまでは、必要なたんぱく質 を本発明のように高比率に配合し、さらにミネラルを十分添加すると沈殿が生じたり、 液の粘度が高くなり経管給与は不可能であった。成分の配合比率、製造法の研究の 結果、低粘度の液状総合経腸栄養組成物を完成し、経管給与を初めて可能とした。 すなわち、その組成物の粘度は 6〜18mPa's(25°C)の範囲にも調整が可能であり、 流動性に優れることが必須の時にはこれを実現できる。さらに、嚥下困難者などへの 給与において、栄養組成物に適度な粘度をつける場合には、低粘性の本発明の総 合経腸栄養組成物に増粘剤を適量加えることにより、患者ごとに適切な粘度をつけ ることがでさる禾 IJ点ち有する。 [0024] Humans with undernutrition are often difficult to ingest orally, and in this case, tube feeding is actively performed through tube feeding. However, until now, the required protein is blended at a high ratio as in the present invention, and further addition of minerals causes precipitation. The viscosity of the liquid increased and tube feeding was impossible. As a result of research on the blending ratio of ingredients and manufacturing method, we have completed a low-viscosity liquid total enteral nutritional composition and made tube feeding possible for the first time. That is, the viscosity of the composition can be adjusted in the range of 6 to 18 mPa's (25 ° C), and this can be realized when excellent fluidity is essential. Furthermore, when giving a proper viscosity to the nutritional composition when feeding it to persons with difficulty in swallowing, etc., by adding an appropriate amount of a thickener to the low-viscosity total enteral nutritional composition of the present invention, It has an IJ point that can be given an appropriate viscosity.
[0025] 本発明の総合経腸栄養組成物は、栄養状態が低下したヒトに提供されるが、例え ば、たんぱく質 ·エネルギー低栄養 (PEM)、低アルブミン血症、低ナトリウム血症、亜 鉛欠乏状態、貧血、ヘモグロビン値およびへマトクリット値の低下、褥瘡あるいは創傷 、免疫能力低下などに苦しむヒトには特に有効である。したがって、これまで有効な 組成物がなカゝつたこれらの人々には本発明の総合経腸栄養組成物は大きな貢献を するものである。 [0025] The total enteral nutrition composition of the present invention is provided to humans with reduced nutritional status. For example, protein / energy undernutrition (PEM), hypoalbuminemia, hyponatremia, zinc It is particularly effective for humans suffering from deficiency, anemia, decreased hemoglobin and hematocrit levels, pressure ulcers or wounds, and decreased immune capacity. Therefore, the total enteral nutrition composition of the present invention makes a great contribution to these people who have had no effective composition so far.
実施例 Example
[0026] 〔実施例 1〕 [Example 1]
総合経腸栄養組成物の調製 (組成物 1) Preparation of total enteral nutrition composition (Composition 1)
低栄養状態に対する最適栄養効果を熟考し、栄養素組成〔表 1〕を組み立てた。こ れを具現化するための液状物の原料配合表を〔表 2〕に示す。乳化安定性に優れ、 たんぱく質等の沈殿を起こさない組成物とするため、ナトリウム原材料とたんぱく質原 材料および乳化剤を原料配合表に従い配合し、高圧乳化機の圧力を 500〜l,OOOk gZcm2として複数回乳化工程を実施することによって、液状総合経腸栄養組成物を 調製した。すなわち、原材料と水とを高圧乳化機を用いて高圧乳化を繰り返し良好な 乳化液を調製した。動物性たんぱく質と植物性たんぱく質の比率は 1 : 1.5とした。ま た、グルタミンペプチドと、大豆たんぱく質あるいはこの加水分解物の比率は 1 : 1.4 であり、さらに脂肪酸糸且成において ω 3系脂肪酸: ω 6系脂肪酸の比率は 1 : 3となる よう配合した。これを通常の充填機を用いてアルミ製袋に充填し、レトルト殺菌機に入 れ、通常の条件で滅菌を実施した。この液は 1年後においても全成分は安定であり、 粘度は 9mPa · s(25°C)であつた。 [0027] [表 1] Considering the optimal nutritional effect for undernutrition, the nutrient composition [Table 1] was assembled. [Table 2] shows the raw material composition table of the liquid material for realizing this. In order to make the composition excellent in emulsification stability and do not cause precipitation of proteins, etc., sodium raw materials, protein raw materials and emulsifiers are blended according to the raw material blending table, and the pressure of the high-pressure emulsifier is set to 500-l, multiples of OOO KZM 2 A liquid integrated enteral nutrition composition was prepared by carrying out a mulch emulsification step. That is, a good emulsion was prepared by repeating high-pressure emulsification of raw material and water using a high-pressure emulsifier. The ratio of animal protein to vegetable protein was 1: 1.5. The ratio of glutamine peptide to soy protein or hydrolyzate was 1: 1.4, and the ratio of ω3-fatty acid: ω6-fatty acid in the fatty acid yarn was 1: 3. This was filled into an aluminum bag using a normal filling machine, placed in a retort sterilizer, and sterilized under normal conditions. Even after one year, all components were stable and the viscosity was 9 mPa · s (25 ° C). [0027] [Table 1]
表 1 : 栄養素組成 1 Table 1: Nutrient composition 1
[0028] [表 2] [0028] [Table 2]
表 2 : 原料配合 1 Table 2: Raw material formulation 1
〔実施例 2〕 Example 2
総合経腸栄養組成物の調製 (組成物 2) Preparation of total enteral nutrition composition (Composition 2)
実施例 1と同様に〔表 3〕に示される栄養素組成を組み立てた。これを具現化するた めの液状物の原料配合表を〔表 4〕に示す。実施例 1と同様に、ナトリウム原材料とた んぱく質原材料および乳化剤の配合量を組み合わせ、さらに高圧乳化機の圧力を5 00〜 1 ,000kgZcm2として複数回乳化工程を実施し、液状総合経腸栄養組成物を 調製した。すなわち、原材料と水とを高圧乳化機を用いて高圧乳化を繰り返し良好な 乳化液を調製した。動物性たんぱく質と植物性たんぱく質の比率は 1:2とした。また 、グルタミンペプチドと、大豆たんぱく質加水分解物の比率は 3:1であり、さらに脂肪 酸組成において ω 3系脂肪酸: ω 6系脂肪酸の比率は 1:1とした。これを通常の充填 機を用いてアルミ製袋に充填し、レトルト殺菌機に入れ、通常の条件で滅菌を実施し た。この液は 1年後においても全成分は安定であり、粘度は 6mPa's (25°C)であった。 The nutrient composition shown in [Table 3] was assembled in the same manner as in Example 1. [Table 4] shows the raw material composition table of the liquid material for realizing this. In the same manner as in Example 1, the sodium raw material, protein raw material, and emulsifier were combined, and the pressure of the high-pressure emulsifier was set to 5. A plurality of emulsification steps were performed at 00 to 1,000 kgZcm 2 to prepare a liquid integrated enteral nutrition composition. That is, a good emulsion was prepared by repeating high-pressure emulsification of raw material and water using a high-pressure emulsifier. The ratio of animal protein to vegetable protein was 1: 2. The ratio of glutamine peptide to soy protein hydrolyzate was 3: 1, and the ratio of ω3-fatty acid: ω6-fatty acid in the fatty acid composition was 1: 1. This was filled into an aluminum bag using a normal filling machine, placed in a retort sterilizer, and sterilized under normal conditions. Even after one year, all components were stable and the viscosity was 6 mPa's (25 ° C).
[0030] [表 3] [0030] [Table 3]
表 3 : 栄養素組成 2 Table 3: Nutrient composition 2
[0031] [表 4] 4 : 2 [0031] [Table 4] 4: 2
〔実施例 3〕 Example 3
総合経腸栄養組成物の調製 (組成物 3) Preparation of total enteral nutrition composition (Composition 3)
実施例 1と同様に〔表 5〕に示される栄養素組成を組み立てた。これを具現化するた めの液状物の原料配合量を〔表 6〕に示す。実施例 1と同様に、ナトリウム原材料とた んぱく質原料および乳化剤を組み合わせ、さらに高圧乳化機の圧力を 500〜1000k g,cm2として複数回乳化工程を実施し、液状総合経腸栄養組成物を調製した。すな わち、原材料と水とを高圧乳化機を用いて高圧乳化を繰り返し良好な乳化液を調製 した。これを通常の充填機を用いてアルミ製袋に充填し、レトルト殺菌機に入れ、通 常の条件で滅菌を実施した。この液は 1年後においても全成分は安定であり、粘度 は lOmPa · s(25°C)であった。 The nutrient composition shown in [Table 5] was assembled in the same manner as in Example 1. [Table 6] shows the amount of raw material blended to realize this. As in Example 1, with sodium raw material The protein raw material and the emulsifier were combined, and the emulsification step was performed a plurality of times by setting the pressure of the high-pressure emulsifier to 500 to 1000 kg, cm 2 to prepare a liquid general enteral nutrition composition. That is, a good emulsion was prepared by repeating high-pressure emulsification of raw material and water using a high-pressure emulsifier. This was filled into an aluminum bag using a normal filling machine, placed in a retort sterilizer, and sterilized under normal conditions. All components of this liquid were stable even after one year, and the viscosity was 10 mPa · s (25 ° C).
[0033] [表 5] 表 5 : 栄養素組成 3 [0033] [Table 5] Table 5: Nutrient composition 3
[0034] [表 6] 6 : 3 [0034] [Table 6] 6: 3
[有効性試験] [Efficacy study]
低栄養モデルにおける発明組成物の栄養状態回復試験 Nutritional state recovery test of invention composition in undernutrition model
SD系雄性ラットを AIN93g飼料力 たんぱく質を除いた無たんぱく食で 3週間飼育 し低栄養モデルを作製した。これらと同様のモデルは事前に実験し、消化管に対し て炎症や壊死など病的変化が見られな 、ことを確認した。これら作製した低栄養ラッ トを無作為に 3群にわけ (各群 7匹)た。経腸栄養組成物の投与は、同一カロリーとし た実施例 1の総合経腸栄養組成物 (A)、実施例 1からグルタミン酸ナトリウムのみを 除き、その窒素量をグリシンで代替して同一にした試験液 (B)、さらに巿販経腸栄養 製品(C)を用いた。試験動物のそれぞれの群に 5日間の間、一日 40kcalの割合で経 腸栄養組成物を胃瘻力 ポンプで投与した。投与 6日目に血液を採取し、総たんぱく 質、アルブミン、血中のナトリウム、カリウム、鉄を測定した。また、各群のラットを解剖 して腸管上皮細胞のジァミンォキシダーゼ (DAO)活性、腸管たんぱく質量を測定し それぞれ栄養指標とした。その結果を表 7に示した。 SD male rats were bred on a protein-free diet excluding AIN93g dietary protein for 3 weeks to create a malnutrition model. Similar models were tested in advance and confirmed that no pathological changes such as inflammation or necrosis were observed in the gastrointestinal tract. These low nutrition rats The groups were randomly divided into 3 groups (7 animals in each group). Administration of enteral nutritional composition is the same calorie test as in Example 1 total enteral nutritional composition (A), except that only sodium glutamate was removed from Example 1, and the nitrogen content was replaced with glycine to make it the same. Liquid (B) and commercial enteral nutrition product (C) were used. Each group of test animals was administered enteral nutritional composition by gastrostomy pump at a rate of 40 kcal per day for 5 days. On day 6 of administration, blood was collected, and total protein, albumin, blood sodium, potassium, and iron were measured. In addition, each group of rats was dissected and measured for intestinal epithelial cell diaminoxidase (DAO) activity and intestinal protein mass, which were used as nutritional indicators. The results are shown in Table 7.
[0036] 表 7に示すように血液検査において、総たん白質さらにアルブミンが実施例 1 (A) において上昇し低栄養力 の回復が明らかとなった。一方、市販栄養製品(C)を投 与した群は、栄養状態の回復が遅れた。この(C)に比べ試験液 (B)は有効であること が認められたが、本発明品である (A)と比較しては劣る結果であった。さらに、血液 中のミネラルを測定した結果、主要ミネラルのナトリウムやカリウム、さらに亜鉛や銅な どの微量元素の代表である鉄についても実施例 1が高値であり、投与されたミネラル の体外損失を防止する効果が認められた。したがって、血液中のヘモグロビンの高 値とも考え合わせると鉄の上昇は貧血や褥瘡に対しても有効である。 [0036] As shown in Table 7, in the blood test, total protein and albumin increased in Example 1 (A), and recovery of low nutritional power was revealed. On the other hand, the group receiving the commercial nutritional product (C) was delayed in recovery of nutritional status. The test solution (B) was found to be more effective than (C), but the results were inferior to those of the product (A) of the present invention. Furthermore, as a result of measuring minerals in the blood, Example 1 has a high value for iron, which is a representative of trace elements such as sodium and potassium as well as zinc and copper, and prevents in vitro loss of the administered minerals. The effect to do was recognized. Therefore, iron elevation is also effective against anemia and pressure ulcers, considering the high hemoglobin level in the blood.
[0037] 他方、低栄養では腸管の上皮の保全をは力ることが難しぐしたがって栄養素の吸 収不全に陥る。今回の実験では実施例 1 (A)で腸管上皮の総たんぱく質が高値に 保たれておりさらに腸管の機能的指標である DAO活性は極めて高値であった。これ は、添加したグルタミン酸ナトリウムが吸収低下の防止効果を示した結果と考えられる 。総合的な判定として、本発明の総合経腸栄養組成物は低栄養状態からの回復に 非常に有効であることが証明された。 [0037] On the other hand, undernutrition makes it difficult to maintain the intestinal epithelium, thus resulting in poor nutrient absorption. In this experiment, the total protein in the intestinal epithelium was maintained at a high level in Example 1 (A), and DAO activity, which is a functional index of the intestinal tract, was extremely high. This is probably because the added sodium glutamate showed the effect of preventing the decrease in absorption. As a comprehensive judgment, it has been proved that the total enteral nutrition composition of the present invention is very effective in recovering from undernutrition.
[0038] [表 7] [0038] [Table 7]
[0039] なお、実施例 2および 3においても同様な実験を行った力 同様な効果が認められ た。 [0039] It should be noted that in Examples 2 and 3, the same effect was observed in the same experiment. It was.
産業上の利用可能性 Industrial applicability
本発明の総合経腸栄養組成物は、含有されるグルタミン酸や 5'—ヌクレオチドの添 加による吸収低下の防止効果によって、たんぱく質 ·エネルギー低栄養 (PEM)のヒト の治療ある ヽは予防のために優れた効果を奏し、栄養指標である血清アルブミン値 の改善、褥瘡の改善、血中で低下したナトリウムやカリウム量の改善、ヘモグロビン値 の改善、へマトクリット値の改善、血清中の鉄や亜鉛などの微量元素量の増加を促す 。したがって、本発明の組成物、特に低アルブミン血症の治療あるいは予防のため、 褥瘡あるいは創傷の治癒、予防のために用いることができる。さらに、本発明の組成 物は高濃度のナトリウムを含有するので、低ナトリウム血症の治療あるいは予防のた めに有用である。さらに、本発明の組成物は高濃度の亜鉛を含有するので、亜鉛欠 乏状態の患者の治療あるいは予防のために用いられる。 The comprehensive enteral nutrition composition of the present invention is effective for the prevention of protein / energy undernutrition (PEM) humans by preventing the decrease in absorption caused by the addition of glutamic acid and 5'-nucleotide. Has excellent effects, improved serum albumin levels as nutritional indicators, improved pressure ulcers, improved sodium and potassium levels decreased in blood, improved hemoglobin levels, improved hematocrit levels, serum iron and zinc, etc. Increase the amount of trace elements. Therefore, the composition of the present invention can be used for treating or preventing hypoalbuminemia, and for healing or preventing pressure ulcers or wounds. Furthermore, since the composition of the present invention contains a high concentration of sodium, it is useful for the treatment or prevention of hyponatremia. Furthermore, since the composition of the present invention contains a high concentration of zinc, it is used for the treatment or prevention of patients who are deficient in zinc.
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008525853A JP5315996B2 (en) | 2006-07-18 | 2007-07-17 | Total enteral nutrition composition |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006-195491 | 2006-07-18 | ||
| JP2006195491 | 2006-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008010472A1 true WO2008010472A1 (en) | 2008-01-24 |
Family
ID=38956803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2007/064056 Ceased WO2008010472A1 (en) | 2006-07-18 | 2007-07-17 | Total enteral nutrition composition |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP5315996B2 (en) |
| WO (1) | WO2008010472A1 (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010054353A (en) * | 2008-08-28 | 2010-03-11 | Hirokazu Shibahara | Method for predicting patient's prognostic health condition improvement degree |
| JP2010051555A (en) * | 2008-08-28 | 2010-03-11 | Hirokazu Shibahara | Patient's health condition evaluating method |
| JP2013529193A (en) * | 2010-04-26 | 2013-07-18 | ネステク ソシエテ アノニム | Nutritional composition and method for withdrawal from parenteral nutrition to enteral nutrition |
| WO2017220934A1 (en) | 2016-06-24 | 2017-12-28 | Arkema France | Nanostructured block copolymer film comprising a biodegradable polyester block |
| WO2018109388A1 (en) | 2016-12-14 | 2018-06-21 | Arkema France | Nanostructured block copolymer film comprising an amorphous block |
| WO2018158545A1 (en) | 2017-03-03 | 2018-09-07 | Arkema France | Polymer electrolyte composition intended to be used in a battery |
| CN109588728A (en) * | 2017-09-30 | 2019-04-09 | 江苏正大丰海制药有限公司 | A kind of oral complete nutritional composition |
| WO2020043995A1 (en) | 2018-08-30 | 2020-03-05 | Arkema France | Polymer, method for the production thereof, composition comprising same, and use in batteries |
| FR3085378A1 (en) | 2018-08-30 | 2020-03-06 | Arkema France | POLYMER, PROCESS FOR PREPARING SAME, COMPOSITION COMPRISING SAME, AND USE IN BATTERIES |
| CN111194912A (en) * | 2019-07-09 | 2020-05-26 | 北京市营养源研究所 | Stable medical liquid enteral nutrition composition and preparation method thereof |
| WO2020109505A1 (en) | 2018-11-30 | 2020-06-04 | Arkema France | Conductive polymer electrolyte for batteries |
| CN112890179A (en) * | 2021-03-01 | 2021-06-04 | 成都尚医信息科技有限公司 | Semi-solidified nutrient for solving enteral nutrition intolerance and preparation method thereof |
| CN116920075A (en) * | 2023-09-15 | 2023-10-24 | 潍坊格菲特生物科技有限公司 | Enteral nutrient solution and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04152861A (en) * | 1990-10-15 | 1992-05-26 | Snow Brand Milk Prod Co Ltd | Nutrient composition for nutrition |
| JP2002510317A (en) * | 1997-07-02 | 2002-04-02 | アボット・ラボラトリーズ | Tasty basic medical composition |
| JP2004041006A (en) * | 2002-07-08 | 2004-02-12 | Meiji Milk Prod Co Ltd | Liquid nutrition composition |
| JP2004051494A (en) * | 2002-07-17 | 2004-02-19 | Nof Corp | Enteral nutrition |
| JP2004091485A (en) * | 2002-08-15 | 2004-03-25 | Terumo Corp | Vitamin b1 containing nutritive composition |
| WO2006001492A1 (en) * | 2004-06-28 | 2006-01-05 | Ajinomoto Co., Inc. | Nutrient composition and composition for prevention/mitigation of digestive tract depression |
| WO2006030980A1 (en) * | 2004-09-17 | 2006-03-23 | Ajinomoto Co., Inc. | Agent and food for preventing/improving functional digestive disorder |
-
2007
- 2007-07-17 JP JP2008525853A patent/JP5315996B2/en not_active Expired - Fee Related
- 2007-07-17 WO PCT/JP2007/064056 patent/WO2008010472A1/en not_active Ceased
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04152861A (en) * | 1990-10-15 | 1992-05-26 | Snow Brand Milk Prod Co Ltd | Nutrient composition for nutrition |
| JP2002510317A (en) * | 1997-07-02 | 2002-04-02 | アボット・ラボラトリーズ | Tasty basic medical composition |
| JP2004041006A (en) * | 2002-07-08 | 2004-02-12 | Meiji Milk Prod Co Ltd | Liquid nutrition composition |
| JP2004051494A (en) * | 2002-07-17 | 2004-02-19 | Nof Corp | Enteral nutrition |
| JP2004091485A (en) * | 2002-08-15 | 2004-03-25 | Terumo Corp | Vitamin b1 containing nutritive composition |
| WO2006001492A1 (en) * | 2004-06-28 | 2006-01-05 | Ajinomoto Co., Inc. | Nutrient composition and composition for prevention/mitigation of digestive tract depression |
| WO2006030980A1 (en) * | 2004-09-17 | 2006-03-23 | Ajinomoto Co., Inc. | Agent and food for preventing/improving functional digestive disorder |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010054353A (en) * | 2008-08-28 | 2010-03-11 | Hirokazu Shibahara | Method for predicting patient's prognostic health condition improvement degree |
| JP2010051555A (en) * | 2008-08-28 | 2010-03-11 | Hirokazu Shibahara | Patient's health condition evaluating method |
| JP2013529193A (en) * | 2010-04-26 | 2013-07-18 | ネステク ソシエテ アノニム | Nutritional composition and method for withdrawal from parenteral nutrition to enteral nutrition |
| WO2017220934A1 (en) | 2016-06-24 | 2017-12-28 | Arkema France | Nanostructured block copolymer film comprising a biodegradable polyester block |
| WO2018109388A1 (en) | 2016-12-14 | 2018-06-21 | Arkema France | Nanostructured block copolymer film comprising an amorphous block |
| WO2018158545A1 (en) | 2017-03-03 | 2018-09-07 | Arkema France | Polymer electrolyte composition intended to be used in a battery |
| CN109588728A (en) * | 2017-09-30 | 2019-04-09 | 江苏正大丰海制药有限公司 | A kind of oral complete nutritional composition |
| WO2020043995A1 (en) | 2018-08-30 | 2020-03-05 | Arkema France | Polymer, method for the production thereof, composition comprising same, and use in batteries |
| FR3085378A1 (en) | 2018-08-30 | 2020-03-06 | Arkema France | POLYMER, PROCESS FOR PREPARING SAME, COMPOSITION COMPRISING SAME, AND USE IN BATTERIES |
| WO2020109505A1 (en) | 2018-11-30 | 2020-06-04 | Arkema France | Conductive polymer electrolyte for batteries |
| FR3089355A1 (en) | 2018-11-30 | 2020-06-05 | Arkema France | CONDUCTIVE POLYMER ELECTROLYTE FOR BATTERIES |
| CN111194912A (en) * | 2019-07-09 | 2020-05-26 | 北京市营养源研究所 | Stable medical liquid enteral nutrition composition and preparation method thereof |
| CN112890179A (en) * | 2021-03-01 | 2021-06-04 | 成都尚医信息科技有限公司 | Semi-solidified nutrient for solving enteral nutrition intolerance and preparation method thereof |
| CN116920075A (en) * | 2023-09-15 | 2023-10-24 | 潍坊格菲特生物科技有限公司 | Enteral nutrient solution and preparation method thereof |
| CN116920075B (en) * | 2023-09-15 | 2024-01-02 | 潍坊市人民医院(潍坊市公共卫生临床中心) | Enteral nutrient solution and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2008010472A1 (en) | 2009-12-17 |
| JP5315996B2 (en) | 2013-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5315996B2 (en) | Total enteral nutrition composition | |
| JP5574561B2 (en) | Total enteral nutrition composition | |
| CN100355420C (en) | Leucine-rich nutritional composition | |
| ES2640728T3 (en) | Liquid enteral nutritional composition based on protein-dense micellar casein | |
| ES2582002T3 (en) | Nutritional composition to improve the immune system of mammals | |
| Moore et al. | The biological value of protein | |
| CN100469361C (en) | Methods and compositions for treating or preventing catabolic or stimulated anabolism in mammals subjected to metabolic stress | |
| WO2012141316A1 (en) | Nutritional composition | |
| US12274284B2 (en) | High-energy food supplement based on inverted sugars and ergogenic products for use in physical activity and method for producing same | |
| CN113194750A (en) | Nutritional composition for inducing satiety, better sleep and/or limiting nighttime arousal in infants or young children | |
| JP2008247748A (en) | Nutritive composition for dialysis patient | |
| JP2009506012A (en) | Nutrients in obese patients | |
| TWI592153B (en) | Methods of promoting the healing of diabetic ulcers using beta-hydroxy-beta-methylbutyrate with arginine and glutamine | |
| CN100448453C (en) | Method for treating or preventing chronic wounds and complete nutritional composition comprising glycine and/or leucine used therein | |
| JP5418956B2 (en) | Total nutritional composition | |
| CN1984571A (en) | A method of improving nutrient utilisation by a mammal and a composition for use therein | |
| EP1972345B1 (en) | Food product for enteral or oral nutrition | |
| JP2004075664A (en) | Intubation-feeding alimentation agent containing coenzyme q10 | |
| TWI712367B (en) | Nutritional composition | |
| EP3773013B1 (en) | Insulin control in overweight or obese adults during a lifelong intervention | |
| CN108378377A (en) | The preparation method and applications of cervical carcinoma full nutrition formula food | |
| TW201825011A (en) | Composition for improving protein efficiency ratio | |
| JPWO1988008259A1 (en) | Nutritional emulsion preparations | |
| ZA200501922B (en) | Leucine-enriched nutritional compositions. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07790818 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2008525853 Country of ref document: JP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| NENP | Non-entry into the national phase |
Ref country code: RU |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07790818 Country of ref document: EP Kind code of ref document: A1 |